Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.60 |
| ▸ | WNT3A | P56704 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7865396 | 0.95 | KMT2A (0.58) | KMT2ACTNNB1WNT3ATDP1MEN1 | |
| SCHEMBL9077880 | 0.89 | KMT2A (0.55) | KMT2ACTNNB1WNT3ATDP1MEN1 | |
| SCHEMBL25456558 | 0.87 | KMT2A (0.53) | KMT2ACTNNB1WNT3ATDP1MEN1 | |
| SCHEMBL16552778 | 0.85 | KMT2A (0.83) | KMT2ACTNNB1WNT3AMEN1NPC1 | |
| SCHEMBL2305014 | 0.85 | HSD17B3 (0.60) | KMT2ATDP1MEN1NPC1RAB9A | |
| SCHEMBL6388993 | 0.84 | KMT2A (0.50) | KMT2ACTNNB1WNT3ATDP1MEN1 | |
| SCHEMBL1201267 | 0.84 | NPC1 (0.62) | KMT2ACTNNB1WNT3ATDP1MEN1 | |
| SCHEMBL9263357 | 0.83 | KMT2A (0.60) | KMT2ATDP1MEN1NPC1RAB9A | |
| SCHEMBL10749473 | 0.83 | KMT2A (0.61) | KMT2ACTNNB1WNT3ATDP1MEN1 | |
| SCHEMBL640759 | 0.83 | LMNA (0.60) | KMT2AMEN1NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119125347-A | Method for detecting succinylcholine chloride intermediate and related impurities | 上海旭东海普药业有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-119125347-A | Method for detecting succinylcholine chloride intermediate and related impurities | 上海旭东海普药业有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-119125347-A | Method for detecting succinylcholine chloride intermediate and related impurities | 上海旭东海普药业有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240150343-A1 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2024-05-09 | — | — | US | disclosed |
| EP-4043462-A1 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2022-08-17 | — | — | EP | disclosed |
| CN-114401964-A | Compound with BRD4 inhibitory activity, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2021068755-A1 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2021-04-15 | — | — | WO | disclosed |
| WO-2021068755-A1 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2021-04-15 | — | — | WO | disclosed |
| CN-112625036-A | Compound with BRD4 inhibitory activity, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2021-04-09 | — | — | CN | disclosed |
| US-8367662-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090176777-A1 | Imidazo (1,2-a)Pyridin-3-YL-Acetic Acid Hydrazides, Proesses for Their Preparation and Pharmaceutical Uses Thereof | FERRER INTERNACIONAL, S.A. (ES) | 2009-07-09 | — | — | US | disclosed |
| US-20090176777-A1 | Imidazo (1,2-a)Pyridin-3-YL-Acetic Acid Hydrazides, Proesses for Their Preparation and Pharmaceutical Uses Thereof | FERRER INTERNACIONAL, S.A. (ES) | 2009-07-09 | — | — | US | disclosed |
| EP-1973907-B1 | IMIDAZO (1,2-A)PYRIDIN-3-YL-ACETIC ACID HYDRAZIDES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL USES THEREOF | FERRER INT (ES) | 2009-05-06 | — | — | EP | disclosed |
| US-7423156-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| WO-2007077159-A1 | IMIDAZO (1,2-A)PYRIDIN-3-YL-ACETIC ACID HYDRAZIDES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL USES THEREOF | FERRER INTERNACIONAL, S.A. (ES) | 2007-07-12 | — | — | WO | disclosed |
| EP-1803722-A1 | Imidazo[1,2-a]pyridin-3-yl-acetic acid hydrazides, processes for their preparation and pharmaceutical uses thereof | FERRER INTERNACIONAL, S.A. (ES) | 2007-07-04 | — | — | EP | disclosed |
| EP-0885869-A1 | THERAPEUTIC AGENT FOR DIABETES | Japan Tobacco Inc. (JP) | 1998-12-23 | — | — | EP | disclosed |
| WO-1992018484-A1 | 3-AMINO-5-ARYLPYRAZOLE-4-ACETIC ACID DERIVATIVES EXHIBITING THERAPEUTIC EFFECTS | A.H. ROBINS COMPANY, INCORPORATED (US) | 1992-10-29 | — | — | WO | disclosed |
| US-5057534-A | Anxiolytic, anticonfulsant and muscle relaxants | A. H. ROBINS COMPANY INCORPORATED (US) | 1991-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150343-A1 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | BRD4, BICRA, BET1 | KMT2A 326/4885CTNNB1 1845/4885WNT3A 1586/4885 |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, LIPC | KMT2A 627/4885CTNNB1 2704/4885WNT3A 1596/4885 |
| US-20090176777-A1 | Imidazo (1,2-a)Pyridin-3-YL-Acetic Acid Hydrazides, Proesses for Their Preparation and Pharmaceutical Uses Thereof | GABRA3, GABRA1, GABRA2 | KMT2A 895/4885CTNNB1 3563/4885WNT3A 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.